The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Feb 2010
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Feb 2010 Actual number of patients (179) added as reported by ClinicalTrials.gov.
- 17 Feb 2010 Planned end date changed from 1 Aug 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.
- 17 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.